AstraZeneca's Ultomiris demonstrated a 43.4% reduction in proteinuria compared to placebo in adults with immunoglobulin A nephropathy at 34 weeks in a Phase III trial, according to interim results presented at the European Renal Association Congress.

The drug showed a 46.6% reduction in 24-hour urine protein creatinine ratio from baseline at week 34, compared to 5.6% in patients receiving placebo. The reduction was observed as early as week 10 and sustained through 34 weeks across patient subgroups.

IgAN is a rare inflammatory kidney disease that can progress to end-stage kidney disease. The condition affects the glomeruli, which filter blood in the kidneys, and approximately half of patients with elevated protein levels are at risk of progression to kidney failure within 10 years of diagnosis.

The I CAN trial enrolled approximately 510 participants across 28 countries. Patients received either Ultomiris or placebo intravenously for 106 weeks while continuing standard care treatments. The study's primary endpoint measuring kidney function changes will be assessed at week 106.

The safety profile was consistent with Ultomiris' known profile. Common adverse events in the treatment group included upper respiratory tract infection (11.3%), nasopharyngitis (9.2%) and infusion-related reactions (8.4%).

Ultomiris (ravulizumab) is a C5 complement inhibitor currently approved for treating paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis and neuromyelitis optica spectrum disorder. The company plans to advance regulatory filings based on these interim data.

AstraZeneca trades on the London Stock Exchange, Stockholm Stock Exchange and New York Stock Exchange under ticker AZN.